Subject:
- Active Substance: Tafasitamab
- Name: Minjuvi®
- Therapeutic area: Diffuse large B-cell lymphoma
- Pharmaceutical company: Incyte Biosciences Germany GmbH
Time table:
- Start: 15.09.2021
- Final decision by G-BA: 03.03.2022
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)